References

  1. Cerazette 75 microgram film-coated tablet Summary of Product Characteristics, December 2007. View [Accessed July 2009]
  2. Rice, C, Killick S, Dieben T, Coelingh Bennick H. A comparison of the inhibition of ovulation achieved by desogestrel 75 µg and levonorgestrel 30 µg daily. Hum Reprod 1999; 14(4): 982–5.
  3. Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 mg/day or levonorgestrel 30 mg/day. Eur J Contracept Reprod Health Care 1998; 3(4): 169–78.
  4. Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75-microg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake. Contraception 2005; 71(1): 8–13.
  5. Ahrendt HJ, Karckt U, Pichl T, et al. The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results from two studies on oestrogen-related symptoms and dysmenorrhoea. Eur J Contracept Reprod Health Care 2007; 12(4): 354–61.
  6. Yasmin film-coated tablets Summary of Product Characteristics, June 2008.
  7. Microgynon 30 Summary of Product Characteristic, December 2008.
  8. Micronor oral contraceptive tablets Summary of Product Characteristics, February 2009.
  9. Noriday tablets Summary of Product Characteristics, March 2004.
  10. Implanon 68 mg implant for subdermal use – Summary of Product Characteristics, October 2008.
  11. Mirena Summary of Product Characteristics, February 2009
  12. Depo-Provera 150mg/ml Injection Summary of Product Characteristics, July 2007.
  13. Schering-Plough Data on File.
  14. Faculty of Family Planning and Reproductive Health Care (FFPRHC). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2005/2006. London: FFPRHC, 2006.
  15. Guillebaud, J. Contraception: Your Questions Answered. 5th edition. Edinburgh: Churchill Livingstone Elsevier, 2009.
  16. Barnhart KT, Schreiber CA. Return to fertility following discontinuation of oral contraceptives. Fertil Steril 2009; 91(3): 659–6.
  17. Hassan MA, Killick SR. Is previous use of hormonal contraception associated with a detrimental effect on subsequent fecundity? Hum Reprod 2004; 19(2): 344–51.

 

 

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to MSD Drug Safety Department on 01707 363773

Organon

Date of Preparation 9/09
Job Code 9/12 - CZT.10.GB.42040.AV

© 2010 Copyright Organon Laboratories Limited. All rights reserved.

Terms and Conditions
Privacy Policy